Drugs / Gammanorm
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02180763 | Apr 2014 → Aug 2016 | immunodeficiency disease | Octapharma | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gammanorm | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02180763 ↗ |
| Action | Restore | “Subcutaneous immunoglobulin replacement therapy (IgRT)” PMID 29855752 ↗ May 2018 |
| Modality | Protein / enzyme biologic | “Subcutaneous immunoglobulin replacement therapy (IgRT)” PMID 29855752 ↗ May 2018 |
| Route | Subcutaneous | “receiving subcutaneous injections of Gammanorm® 165 mg/mL” NCT02180763 ↗ |